CA
NZ
UK
AU
IND
US
Jiangsu Hengrui Pharmaceuticals Co., Ltd. filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 7,420,091 shares of common stock in Braveheart Bio, Inc. (NASDAQ:BRVE), representing 8.2% of the company's outstanding shares as of September 30, 2026.
ConnectM Technology Solutions, Inc. filed Amendment No. 4 to its Form S-1 registration statement with the U.S. Securities and Exchange Commission on November 6, 2026, covering a proposed firm commitment public offering of up to 3,735,000 shares of common stock and accompanying warrants.
Citigroup Global Markets Holdings Inc. filed a Free Writing Prospectus on November 6, 2026, disclosing the offering summary for Contingent Income Callable Securities due November 2028, linked to the worst performing of the EURO STOXX 50, Russell 2000, and S&P 500 indices.
HSBC Holdings plc filed a Form 6-K with the SEC on 9 November 2026 announcing an investor and analyst briefing on its UK business, hosted by HSBC UK Bank plc CEO David Lindberg and CFO Jonathan Bingham at the company's London office.
Windward Bio Group AG filed Amendment No. 2 to its Form F-1 registration statement with the U.S. Securities and Exchange Commission on November 9, 2026, covering a proposed initial public offering of 10,294,117 common shares at an estimated price range of $16.00 to $18.00 …
Artificial Intelligence Technology Solutions Inc. filed a current report on November 9, 2026, disclosing a press release from its RAD division announcing a new product called RAIA, described as a security tower designed for self-setup by the end user.
Prudential plc filed a Form 6-K with the SEC on 9 November 2026 disclosing the repurchase of 2,751,671 ordinary shares on the London Stock Exchange between 2 and 6 November 2026, executed through JP Morgan Securities plc.
Charles River Laboratories International, Inc. filed a Form 8-K on November 9, 2026, disclosing that it has entered into definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations located in Exton, Pennsylvania.
Canton Strategic Holdings, Inc. filed a Form 8-K on November 9, 2026, disclosing that on November 4, 2026, the company announced the first trade of tokenized shares of its common stock on TSV LLC.
Director Michael R. Splinter filed a Form 4 with the SEC on November 9, 2026, disclosing a purchase of 840 American Depositary Shares of Taiwan Semiconductor Manufacturing Co Ltd on November 5, 2026, at a price of $357 per share.
Please wait processing your request...